Some prior studies have linked DPP-4 inhibitors (Zhang et al., 2017; Pinto et al., 2018), GLP-1 receptor agonists (Faillie et al., 2014), and Metformin (Mallick, 2004) to an increased risk of AP, but the mechanism of action remains unclear. This evidence concerns the gene GLP1R and alkaline phosphatase measurement.